Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
US Stock MarketDetailed Quotes
VYGR Voyager Therapeutics
- 3.740
- +0.100+2.75%
Close Mar 27 16:00 ET
- 3.740
- 0.0000.00%
Post 20:01 ET
206.47MMarket Cap-3.31P/E (TTM)
3.785High3.580Low235.39KVolume3.580Open3.640Pre Close872.57KTurnover0.52%Turnover RatioLossP/E (Static)55.21MShares10.66052wk High0.69P/B168.77MFloat Cap3.56052wk Low--Dividend TTM45.13MShs Float31.910Historical High--Div YieldTTM5.63%Amplitude2.460Historical Low3.706Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Voyager Therapeutics Stock Forum
● Collaboration Revenues: Voyager had collaboration revenue of $6.3 million for the fourth quarter of 2024, compared to $90.1 million for the same period in 2023, and $80.0 million for the year ended December 31, 2024, compared to $250.0 million for the same period in 2023. The decrease was primarily due to decreased revenue recognized under our Neurocrine and Novartis collaboration agr...
Dow Jones· 1 min ago
Very oversold, less than 1% profitable positions, undervalued by all except p/e which is still under market avg.
This was over $10 recently, and earnings were great, except Wall St was scared of recession at the time. I'm guessing once they are satisfied, this will go back up
Dow Jones· 2 mins ago
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabl...
No comment yet